Mymetics Corporation  (MYMX)
Other Ticker:  
Price: $0.0100 $0.01 525.000%
Day's High: $0.01 Week Perf: 733.33 %
Day's Low: $ 0.01 30 Day Perf: 1328.57 %
Volume (M): 0 52 Wk High: $ 0.03
Volume (M$): $ 0 52 Wk Avg: $0.01
Open: $0.01 52 Wk Low: $0.00

 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 304
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Mymetics Corporation
Mymetics Corporation is a biotechnology company specializing in the development of novel vaccine and drug delivery technologies. The company focuses on creating innovative solutions to improve the efficacy and safety of vaccines and drugs.

Mymetics' core technology, called virosome-based vaccine adjuvants, involves the reengineering of viruses to enable them to deliver antigens effectively to the immune system for a robust immune response. This approach allows for the development of vaccines against various infectious diseases, including respiratory syncytial virus (RSV), malaria, and HIV.

Additionally, the company is involved in research and development related to mucosal drug delivery, aiming to enhance the effectiveness and convenience of drug administration through the mucosal surfaces of the body. They leverage their expertise in virosome technology for this purpose as well.

Mymetics collaborates with various partners, including pharmaceutical companies, governmental organizations, and research institutes, to advance their technologies and bring their products to market. They also actively seek partnerships and licensing opportunities to further expand their reach and impact in the field of vaccine and drug delivery.

Overall, Mymetics Corporation is dedicated to pioneering innovative approaches in vaccine and drug delivery to address critical global health challenges and improve patient outcomes.

   Company Address: c/o Mymetics SA Epalinges 1066
   Company Phone Number: 41 21 566 57 72   Stock Exchange / Ticker: MYMX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Mymetics Corporation

Mymetics Corporation Faces Challenging Performance in Q3 2023 as Earnings Decline

Financial News Report: Mymetics Corporation Earnings Decline in Q3 2023
Mymetics Corporation, a leading company in the XYZ industry, recently released its financial earnings report for the third quarter of 2023. The results showcase a decline in earnings and revenue compared to the previous year and the previous reporting period.
During the third quarter of 2023, Mymetics Corporation reported earnings per share (EPS) of $0.00. This is the same figure as the previous year but a decrease compared to the previous reporting period. This stagnant growth in earnings per share suggests that the company's profitability remained unchanged.

Mymetics Corporation

Mymetics Corporation Reports Significant Revenue Contraction throughout the Financial Period Ending June 30, 2023

Mymetics Corporation recently released its financial results for the most recent fiscal period, revealing a balance sheet of $0.00 per share. However, this did not indicate favorable growth or improvements as it was the same as the previous year and prior reporting period. Additionally, the revenue decreased by 37.71% to $0.21 million compared to $0.33 million in the same reporting period a year before. Notably, the net loss for the most recent fiscal period was much larger, amounting to $-8.607 million, a significant increase from $-1.503 million recorded a year ago. These results highlight some challenges that the company may face moving forward.
Decreasing Revenue:
The most concerning aspect of Mymetics Corporation's financial results is the decline in revenue. The company experienced a significant drop of 37.71%, from $0.33 million to $0.21 million, in a year-over-year comparison. This decline indicates a slowing demand for the company's products and services. Moreover, sequentially, the revenue tumbled by 33.213% from $0.31 million. Such a decline may raise questions regarding the company's ability to achieve sustainable growth in the future.

Mymetics Corporation

Mymetics Corporation Reports Fiscal Year 2023 Net Loss of $-7 Million, Resulting in a Disappointing -92.32% Return on Assets

Mymetics Corporation, a Biotechnology & Pharmaceuticals company, has recently reported a net loss for the fiscal year ending in the first quarter of 2023, amounting to $-7 million. This substantial loss has resulted in the company recording a negative return on assets (ROA) of -92.32%, a disappointing outcome for investors and stakeholders alike.
In comparison to other companies in the Healthcare sector, 693 entities had a higher return on assets, further highlighting Mymetics Corporation's underperformance. However, there is some hope for the company as they have seen an improvement in their overall ranking, moving to 3466 from 4813 in the fourth quarter of 2022.


Mymetics's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com